Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings ...
Entering a catalyst-rich period, Novartis expects 15+ potentially submission-enabling readouts over the next two years. With significant replacement power and a robust pipeline featuring 30+ potential ...
Marks latest milestone in company’s previously announced $23 billion investment in US infrastructure ...
. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...
Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...
. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...
About Novartis Immunology At Novartis, we’re advancing bold science for autoimmune diseases, where meaningful therapeutic progress has long stalled. With a growing legacy of first-in-class innovation ...
. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...
When do conversations around breast health begin? Formally, they often start in grade school, when lessons on puberty introduce the idea of developing breasts. But informally, the conversations are ...
Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-controlled ...
Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025 DTP offering to expand to other appropriate products; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback